These data suggest that, as for selective DAT inhibitors, the value of mixed DAT = NET inhibitors in PD may be as L-DOPA-sparing agents, possibly early in the disease process, whereas there is at present no rationale to support their use in advanced disease, as adjunct therapy, to alleviate wearing-off. Here, SLC6A2 is linked to Parkinson disease.